<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title>Frontiers in Psychiatry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Psychiatry</abbrev-journal-title>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fpsyt.2022.975674</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Dual disorders (addictive and concomitant psychiatric disorders): Mechanisms and treatment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Vorspan</surname> <given-names>Florence</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/983208/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Brousse</surname> <given-names>Georges</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/127677/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Van Den Brink</surname> <given-names>Wim</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1786091/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Universit&#x000E9; de Paris Cit&#x000E9;, UFR de M&#x000E9;decine, INSERM UMRS1144</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff2"><sup>2</sup><institution>Assistance Publique &#x02013; H&#x000F4;pitaux de Paris, GHU.NORD, H&#x000F4;pital Fernand Widal</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff3"><sup>3</sup><institution>Universit&#x000E9; Clermont Auvergne, CNRS Institut Pascal, Clermont Auvergne INP</institution>, <addr-line>Clermont-Ferrand</addr-line>, <country>France</country></aff>
<aff id="aff4"><sup>4</sup><institution>Centre Hospitalier Universitaire de Clermont-Ferrand</institution>, <addr-line>Clermont-Ferrand</addr-line>, <country>France</country></aff>
<aff id="aff5"><sup>5</sup><institution>Service D&#x00027;addictologie, Amsterdam University Medical Centers, Location Academic Medical Center, University of Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country>Netherlands</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited and reviewed by: Yasser Khazaal, University of Lausanne, Switzerland</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Florence Vorspan <email>florence.vorspan&#x00040;lrb.aphp.fr</email></corresp>
<fn fn-type="other" id="fn001"><p>This article was submitted to Addictive Disorders, a section of the journal Frontiers in Psychiatry</p></fn>
<fn fn-type="equal" id="fn002"><p>&#x02020;These authors have contributed equally to this work</p></fn></author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>08</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>975674</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>06</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>07</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2022 Vorspan, Brousse and Van Den Brink.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Vorspan, Brousse and Van Den Brink</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license> </permissions>
<related-article id="RA1" related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/research-topics/20450/dual-disorders-addictive-and-concomitant-psychiatric-disorders-mechanisms-and-treatment" ext-link-type="uri">Editorial on the Research Topic <article-title>Dual disorders (addictive and concomitant psychiatric disorders): Mechanisms and treatment</article-title></related-article>
<kwd-group>
<kwd>comorbidity</kwd>
<kwd>co-occurrence</kwd>
<kwd>dual disorders</kwd>
<kwd>psychiatry</kwd>
<kwd>addiction</kwd>
<kwd>pathophysiology</kwd>
<kwd>association</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="2"/>
<word-count count="1242"/>
</counts>
</article-meta>
</front>
<body>
<p>When we launched this Research Topic dedicated to &#x0201C;<italic>Dual Disorders: Mechanisms and Treatment</italic>&#x0201D; we were highly ambitious. We wanted to offer the opportunity to colleagues all over the world to use it as a window to show their latest research findings. We were especially eager to read and publish new empirical evidence on the nature of the relationship between addiction and other psychiatric disorders as well as new empirical evidence on the treatment of dual disorders.</p>
<p>Indeed, we already know since several decades, that dual disorders, i.e., the comorbidity between addictive and other psychiatric disorders, are the rule rather than the exception. The high prevalence of dual disorders and their association with worse outcomes, not only related to poor compliance, are already well-documented.</p>
<p>The debate on the mechanisms leading to dual disorders as either the result of a self-medication by psychiatric patients, the result of repetitive substance use toxicity on brain functions such as mood dysregulation, or the result of some shared biological (e.g., genetic) or environmental (e.g., childhood adversity) factor, will not be solved by this Research Topic, but the 12 articles published are a good reflection of current researchers&#x00027; concerns.</p>
<p>Two published articles from this Research Topic are literature reviews. The first one is a general review on how Research Domain Criteria (RDOC) could serve as a basis of dual disorders research (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2022.805163">Hakak-Zargar et al.</ext-link> from Canada) taking examples in several specific dual disorders. The second one is dedicated to one dual disorder: the co-occurrence a Post-Traumatic Stress Disorder (PTSD) and one or several addictive disorders (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2021.786664">Renaud et al.</ext-link> from France). The authors have read the literature with a specific focus on the mechanisms linking PTSD symptoms and craving, trying to identify a mechanism behind the worse prognosis of addictions in Substance Use Disorders (SUD) patients <italic>with</italic> compared to SUD patients <italic>without</italic> PTSD.</p>
<p>There are also ten studies with original data published in this Research Topic. Three are cross-sectional studies conducted in the general population, exploring potential mechanisms causing dual disorders. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2021.790704">Bourduge et al.</ext-link> from France, explored through questionnaires the association between the first lockdown in French teenagers, coping strategies and substance use, as a model of adaptation disorders. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2022.813545">&#x000C1;goston et al.</ext-link> in a collaborative work conducted between Hungary and the Netherlands, observed the link between a higher score to a caffeine dependence screening scale and a higher score to adult Attention Deficit/Hyperactivity Disorders (ADHD) screening score, that can serve for a model of the association of stimulant abuse and adult ADHD. Finally, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2022.792206">El Archi et al.</ext-link> from France, conducted an internet survey showing the link between a screening questionnaire of gambling disorder and a screening score of adult ADHD, but also depressive symptoms.</p>
<p>The last seven studies, all conducted in patient samples using various methodologies. Three of them were cross-sectional descriptive studies.</p>
<p><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2021.775670">Cab&#x000E9; et al.</ext-link> from France, showed a significant association between symptoms of a &#x0201C;high&#x0201D; during cocaine use and the self-report of depression during cocaine &#x0201C;downs.&#x0201D; <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2022.813256">Icick et al.</ext-link> in a collaborative study comparing bipolar patients treated in expert centers in France and Norway, observed statistically different prescribed treatments according to the presence of specific SUDs (cannabis, alcohol, or tobacco use disorder). Lastly, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2022.821432">Barrangou-Poueys-Darlas et al.</ext-link> from France, descripted the prevalence of a high score on ADHD screening scales and anxiety disorders in patients in care for Gambling Disorders.</p>
<p>Four prospective experimental studies conducted in patients open an avenue for intervention studies in patients with dual disorders.</p>
<p><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2022.803227">Therribout et al.</ext-link> from France, describe their stringent methodology to assess ADHD diagnosis in patients with severe SUD. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2021.659527">Cardullo et al.</ext-link> from Italy, conducted a secondary analysis of a prospective r-TMS trial comparing cocaine use disorder patients with and without comorbid ADHD. They did not show a difference in the treatment response between the two groups. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2021.794014">Todesco et al.</ext-link> from Canada, studied the predictive power of a decision-making test among treatment seeking dual disorder patients, showing that 4 dimensions of this test predicted drop-out in these patients. Lastly, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fpsyt.2022.836771">Fonseca et al.</ext-link> from Spain, prospectively (90 days) studied patients with a major depression with and without cocaine use disorder, assessing cortisol and BDNF levels. Their results suggest that the combination of cortisol and BDNF plasmatic levels could differentiate primary vs. cocaine-induced major depression.</p>
<p>This variety of articles show that dual disorders research is moving forward. On the one hand research involves more and more specific association of pairs of psychiatric and addictive disorders, and on the other hand recent research tries to better understand the mechanisms behind the occurrence or severity of dual disorders. Specific therapeutic studies matching treatments with certain patient characteristics are at reach. We hope that reading those articles will give you plenty of new ideas to move this field forward. Patients suffering from dual disorders are still in great need of effective treatments, and high quality research aiming at changing the poor prognosis of these co-occurring conditions is warranted.</p>
<sec id="s1">
<title>Author contributions</title>
<p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p>
</sec>
<sec sec-type="COI-statement" id="conf1">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s3">
<title>Publisher&#x00027;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
</article>